Loading data for BLSM — first visit, this takes a few seconds.
BlossomHill Therapeutics ... (BLSM)
NasdaqGS: BLSM
· Precio en tiempo real · USD
16.10
-0.28 (-1.71%)
Al cierre: Aug 18, 2026, 8:00 PM
BlossomHill Therapeutics Inc. (BLSM) Stock Price, Analysis & Data
-1.71% (1D)
No hay datos disponibles
| Precio de compra | n/a |
| Capitalización de mercado | 468.21M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -71.08M |
| Beta | n/a |
| EPS (TTM) | -3.41 |
| Ratio PER (TTM) | n/a |
| Adelante PE | n/a |
| P/B (TTM) | -0.28 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | 307,915 |
| Volumen medio (20D) | 522,150 |
| Abierto | 16.58 |
| Anterior Cerrar | 16.38 |
| Rango del día | 15.96 - 16.73 |
| Rango de 52 semanas | 15.25 - 17.25 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de BLSM
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (...
Industria Biotechnology
Sector Healthcare
IPO Fecha Aug 7, 2026
Empleados 63
Bolsa de Valores NasdaqGS
Símbolo bursátil BLSM
Sitio web https://bhtherapeutics.com
Desempeño financiero
En 2025, los ingresos de BlossomHill Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -60.55M, un aumento de 97.28%.
Estados financieros